Almatica Pharma LLC
$421.9K 15,812 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Cepheid
Cepheid reported $423,399.92 across General Payments, Research, and Ownership to 260 physicians and teaching hospitals across 271 transactions.
- $423.4K Above-median payer
- All-tracks total
- 271 Above-median volume
- Transactions
- 260 Above-median reach
- Recipients
- +$264.6K
- General Payments vs PY2023
Cepheid reported $423,399.92 across all CMS Open Payments tracks (General + Research + Ownership) to 260 physicians and teaching hospitals in Program Year 2024 - ranking #803 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $408,399.92, averaging $1.6K per recipient.
How Cepheid's $423.4K all-tracks total breaks down
Cepheid's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
25/100
Total payments
F
14/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cepheid Cepheid
$423.4K · #803/1,925 · 0.0% industry · PY2024
- TOT $423.4K
- RANK #803
- SHARE 0.0%
- TXN 271
- RCP 260
- CAT 5
- GEN $408.4K
- ΔGEN +$264.6K
- TOP1 65.1%
- PY 2024
Volume peers
Nearest volume peer: Almatica Pharma LLC ($421.9K)
Cepheid sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Cepheid's CMS-reported General Payments increased by $264.6K (+184.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CEPHEIDPY2023: CEPHEIDPY2024: Cepheid. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $143,785.06
- PY2024
- $408,399.92
What the Data Shows for Cepheid
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Cepheid, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Consulting Fee" leads the 5-category general-payment breakdown below at $281.7K (69.0% of General Payments, 19 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 5 types of general payments, Cepheid's largest category was "Consulting Fee" at $281.7K - 69.0% of General Payments.
Cepheid reports 5 general-payment categories - the top three are Consulting Fee (69.0%), Compensation for Faculty or Speaker (Medical Education) (21.8%), and Travel and Lodging (7.1%). The remaining 2 categories make up 2.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Cepheid divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $281.7K | 19 | 69.0% |
| Compensation for Faculty or Speaker (Medical Education) | $89.0K | 41 | 21.8% |
| Travel and Lodging | $29.1K | 40 | 7.1% |
| Food and Beverage | $5.5K | 151 | 1.4% |
| Compensation for Services Other Than Consulting | $3.0K | 9 | 0.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $319,994.24 (78.4%) of $408,399.92 in this company's General Payments records across 158 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Cepheid
The five named recipients with the highest reported General Payments from this company
- 1
Lee Fleisher
$265,936.42 across 15 reported transactions
- 2
Rebecca Lillis
$17,005.64 across 14 reported transactions
- 3
Bryant Boyd
$13,539.29 across 10 reported transactions
- 4
Dov Shapiro
$12,189.04 across 11 reported transactions
- 5
Daniel Barbaro
$11,323.85 across 10 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Cepheid ranks #803 of 1,925 by total payments (top 42% by spend) but is notably more concentrated than that alone would suggest -- #424 of 1,838 by HHI (top 23% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Spectra Medical Devices, LLC : $2.7K total payments, HHI 4434
- Meticuly Inc. : $1.6K total payments, HHI 4429
- Eton Pharmaceuticals, Inc. : $80.6K total payments, HHI 4392
- Circinus Medical Technology LLC : $5.3K total payments, HHI 4376
- Kinamed, Inc. : $23.8K total payments, HHI 4353
- Joline Medical Inc : $2.6K total payments, HHI 4318
- Cepheid (this company) : $408.4K total payments, HHI 4315
- Hoya Surgical Optics, Inc : $11.7K total payments, HHI 4312
- PolarisAR Inc : $22.6K total payments, HHI 4312
- Medicem Inc. : $119.3K total payments, HHI 4304
- Oasis Medical, Inc. : $94.3K total payments, HHI 4288
- Consortium of Independent Immunology Clinics, LLC : $225.3K total payments, HHI 4285
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Cepheid's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Cepheid.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Cepheid.
Showing 6 of 1,924 companies with CMS-reported payment data.
Rayner Intraocular Lenses Limited
$421.7K 2,145 recipients
Compare payment profiles
Bio-Rad Laboratories, Inc.
$421.2K 810 recipients
Compare payment profiles
CeQur Corporation
$420.1K 9,797 recipients
Compare payment profiles
Sequoia Surgical Distributors, LLC
$427.6K 16 recipients
Compare payment profiles
WyCo Surgical Distribution LLC
$418.5K 0 recipients
Compare payment profiles
Put this to use
Cepheid ranks #803 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Cepheid. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.